<DOC>
	<DOCNO>NCT03099278</DOCNO>
	<brief_summary>Ezetimibe possess pharmacophore feature inhibit NTCP , receptor require HBV HDV hepatocyte entry include two hydrophobes one hydrogen bond acceptor . Therapy Ezetimibe may lead decline hepatitis D virus level . The aim study evaluate utility Ezetimibe patient chronic HDV infection</brief_summary>
	<brief_title>Ezetimibe Patients With Chronic Hepatitis D</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis D</mesh_term>
	<mesh_term>Hepatitis D , Chronic</mesh_term>
	<mesh_term>Ezetimibe</mesh_term>
	<criteria>Treatment experience patient ; nonresponders relapsers pegylated interferon therapy Age 18 year Presence antiHDV serum Presence quantifiable HDV RNA serum Elevated ALT &gt; ULN Decompensated liver disease Patients ALT level great 10 time ULN ( 400 U/L ) Pregnancy inability practice adequate contraception . Significant systemic major illness liver disease , include , limited , congestive heart failure , renal failure ( eGFR &lt; 50 ml/min ) , organ transplantation , serious psychiatric disease depression active coronary artery disease . Systemic immunosuppressive therapy Evidence another form liver disease addition viral hepatitis Active substance abuse , alcohol injection drug Hepatocellular carcinoma Concurrent hepatitis C infection HIV coinfection Diagnosis malignancy five year Concurrent usage statin Concurrent use drug know inhibit NTCP Inability understand sign inform consent Any condition , opinion investigator would impede patient 's participation compliance study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>hepatitis D</keyword>
	<keyword>Ezetimibe</keyword>
	<keyword>HDV RNA</keyword>
</DOC>